濮阳东方医院看男科非常好濮阳东方医院男科治疗阳痿价格公开,濮阳东方妇科医院做人流评价好很专业,濮阳东方医院男科治疗阳痿口碑非常高,濮阳市东方医院治病便宜吗,濮阳东方医院男科治早泄收费比较低,濮阳东方医院看阳痿口碑很高,濮阳东方医院治阳痿收费合理

SAN FRANCISCO, Dec. 29 (Xinhua) -- The United States Patent and Trademark Office on Thursday published a patent application from Apple related to face and presence detection for iOS devices, which is expected to be one of the next chapters for mobile security.According to AppleInsider, a news and rumor website focusing on Apple, the patent is entitled "low threshold face recognition" which is a low-computation solution for quickly and accurately recognizing a user on iPhone, iPad, iPod Touch and MacBook.Patently Apple, a blog focusing on Apple's latest intellectual properties, said that iOS devices would acknowledge the presence of the potential user by turning on the display and then trigger a subsequent process for recognizing the potential user's face.Currently, most face recognition systems tend to be robust ones working in various lighting conditions, orientations, scale and etc., which will require computing resources and drain battery life. There are also security-type face recognition systems working under controlled lighting conditions which could be ineffective due to factors like proximity of the user to the camera.Google's latest Android 4.0 operating system, codenamed Ice Cream Sandwich, already features face detection. But it is reported that the feature doesn't always work and can be bypassed by using a photograph of the phone's owner.Apple's solution would reduce the impact of lighting conditions and biometric distortions on an image, said AppleInsider, citing the filing. Apple said it would rely on a "high information portion" of a human face, such as eyes, mouth or the tip of a user 's nose.The "likely presence" of a human face in front of the camera would be captured through an "orange-distance filter" which would also be used to detect the potential user's skin tone and measure the distance of their face from the camera.Meanwhile, iOS devices could also be set to recognize faces of multiple users, presenting each user with a personalized configuration.According to AppleInsider, the patent application was first filed by Apple in June, 2009.Analysts said that the proposed technology could be Apple's next big innovation as it has record of redesign and give its unique appeal to products that have not caught on with the general public.

BRUSSELS, Nov. 7 (Xinhua) -- China and Europe should strive to strengthen their cooperation for a win-win outcome in this era of profound changes, said a senior Chinese official here on Monday.Liu Yunshan, a member of the Political Bureau of the Communist Party of China (CPC) Central Committee, made the remarks during his keynote speech at the opening ceremony of the China-Europe High-Level Political Party Forum.Chinese President Hu Jintao has expressed a readiness to work for world economic recovery and strong, balanced and sustainable growth at the G20 summit in Cannes, France last week, said Liu, who is also head of the Publicity Department of the CPC.Liu Yunshan(Front, 3rd,R), a member of the Political Bureau of the Communist Party of China (CPC) Central Committee, attends the opening ceremony of the China-Europe High-Level Political Party Forum in Brussels on Nov. 7, 2011. The forum kicked off in Brussels on Monday.The forum would carry on with discussions on the new possibility and new measures of cooperation between China and Europe, which would add new spurs to their relations, said the Chinese official.Liu called for more cooperation for a win-win result and mutual respect for cultural differences between China and Europe, as well as a common effort to build an inclusive and open international system to face up to global challenges.Noting that China and Europe are stepping into a new stage of development for their ties, Liu expressed hopes that both sides further enhance their strategic mutual trust, "respect each other's core interest and major concerns and observe each other's development from a more objective perspective."Efforts should be made to promote their cooperation in trade, finance, environment protection, high-tech and new energy, and China and Europe should also work to cultivate new growth possibilities for their economic and trade cooperation, he said.They should in the meanwhile expand people-to-people exchanges and take the chance of their intercultural dialogue year in 2012 to build on their friendship, he added.Leaders from the European political parties said the forum offered chance for a key high-level dialogue for the political parties in China and Europe, which would play an active role for the exchanges and comprehensive development of the relations between both sides.

BEIJING, Dec. 30 (Xinhua) -- China's quality watchdog said Friday that the latest checks by testing organizations did not find excessive levels of aflatoxin in milk products made by Chinese dairies.The special checks were launched after the General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ) reported on Dec. 23 that two batches of milk products made by two separate domestic dairies, including heavyweight Mengniu Dairy Group, were found to contain high levels of the cancer-causing toxin.A brief statement on the government agency's website Friday said the checks have covered major makers, including Mengniu, Yili Industrial Group, Bright Dairy, and Sanyuan Food.An AQSIQ official said earlier the toxin had originated from cows eating mildewed feed, citing reviews by experts. The toxin would disappear if the animals stop eating the rotten feed, the official said.Aflatoxin is produced by a fungus that commonly grows on crops such as grain and peanuts. High levels of the toxin may lead to cancer in some animals.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

WASHINGTON, Dec. 5 (Xinhua) -- NASA's Kepler mission has confirmed its first planet in the "habitable zone," a region where liquid water could exist on a planet's surface, the U.S. space agency announced on Monday.The newly-confirmed planet, Kepler-22b, is the smallest yet found to orbit in the middle of the habitable zone of a star similar to Sun. The planet is about 2.4 times the radius of Earth. Scientists don't yet know if Kepler-22b has a predominantly rocky, gaseous or liquid composition, but its discovery is a step closer to finding Earth-like planets.Previous research hinted at the existence of near-Earth-size planets in habitable zones, but clear confirmation proved elusive. Two other small planets orbiting stars smaller and cooler than Sun recently were confirmed on the very edges of the habitable zone, with orbits more closely resembling those of Venus and Mars.Kepler-22's star is a bit smaller than our sun, so its habitable zone is slightly closer in. The diagram shows an artist's rendering of the planet comfortably orbiting within the habitable zone, similar to where Earth circles the sun. Kepler-22b has a yearly orbit of 289 days. The planet is the smallest known to orbit in the middle of the habitable zone of a sun-like star. It's about 2.4 times the size of Earth."This is a major milestone on the road to finding Earth's twin, " said Douglas Hudgins, Kepler program scientist at the NASA Headquarters in Washington. "Kepler's results continue to demonstrate the importance of NASA's science missions, which aim to answer some of the biggest questions about our place in the universe."Kepler discovers planets and planet candidates by measuring dips in the brightness of more than 150,000 stars to search for planets that cross in front, or "transit," the stars. Kepler requires at least three transits to verify a signal as a planet."Fortune smiled upon us with the detection of this planet," said William Borucki, Kepler principal investigator at the NASA Ames Research Center who led the team that discovered Kepler-22b. "The first transit was captured just three days after we declared the spacecraft operationally ready. We witnessed the defining third transit over the 2010 holiday season."The Kepler science team uses ground-based telescopes and the Spitzer Space Telescope to review observations on planet candidates the spacecraft finds. The star field that Kepler observes in the constellations Cygnus and Lyra can only be seen from ground-based observatories in spring through early fall. The data from these other observations help determine which candidates can be validated as planets.Kepler-22b is located 600 light years away. While the planet is larger than Earth, its orbit of 290 days around a Sun-like star resembles that of Earth. The planet's host star belongs to the same class as Sun, called G-type, although it is slightly smaller and cooler.Of the 54 habitable-zone planet candidates reported in February 2011, Kepler-22b is the first to be confirmed. This finding will be published in The Astrophysical Journal.